###### Strengths and limitations of this study

-   The results of this systematic review and meta-analysis are highly dependent on the quality of the included primary research studies, and only randomised controlled trials were included in this study.

-   Subgroup analyses were performed according to clinical heterogeneity analysis of the included studies.

-   This was the first review to systematically examine the impact of vitamin D supplementation on ventricular remodelling in patients with heart failure.

-   The results suggest that vitamin D may be used as adjunctive heart failure medication in heart failure patients with an underlying lack of or insufficiency in vitamin D.

-   The results need to be interpreted with caution as there were few studies in each subgroup.

Introduction {#s1}
============

Heart failure (HF) is the main factor leading to economic loss due to poor prognosis and a high mortality rate.[@R1] In the USA, there are at least 5 000 000 patients with decreased contractile function; meanwhile, there is also the same number of patients with the same disease in Western Europe.[@R2] In recent years, the prognosis of HF has improved remarkably, and the 5-year survival rate has increased from 43% to 52%.[@R4] At present, the main treatment methods for HF are still β-receptor blocking agents, ACEI/angiotensin receptor blocker and aldosterone receptor antagonists; although these medications can reduce the incidence of adverse cardiac events and improve cardiac function,[@R5] HF is still a main cause of global mortality. Therefore, there is presently an urgent need for supplementary treatment methods and strategies. Lack of or insufficiency in vitamin D may result in cardiovascular and cerebrovascular diseases.[@R6] Many studies have discovered that[@R11] there is a remarkable association between lack of vitamin D and the progression of HF. Studies have shown that patients with HF generally lack vitamin D and have a poor prognosis; moreover, supplementation of vitamin D could reduce the mortality rate of patients with HF.[@R15] Several studies have shown that vitamin D acts as a negative regulator of the renin--angiotensin--aldosterone system (RAAS)[@R18] and modulates myocardial extracellular matrix turnover. Consistently, vitamin D receptor (VDR) knockout mice show increased RAAS activity, which leads to hypertension, cardiac hypertrophy, increased water intake and sodium retention,[@R18] and VDR knockout mice show increased metalloprotease activity, which promotes the destruction of myocardial tissue, leading to ventricular remodelling.[@R21] Therefore, lack of vitamin D could result in deterioration of heart function and accelerate myocardial remodelling.

At present, different studies have reported controversial conclusions regarding the influence of vitamin D on ventricular remodelling in patients with HF. Therefore, the present study performed a meta-analysis to further clarify the influence of vitamin D on ventricular remodelling in patients with HF.

Materials and methods {#s2}
=====================

Search strategy {#s2a}
---------------

PubMed, EMBASE, Cochrane Central Register of Controlled Trials, CNKI and Web of Science were searched. Grey literature was also retrieved in Opengrey and ProQuest. The reference lists of identified articles and the bibliographies of original articles were also reviewed. The medical subject headings used in the search were as follows: "heart failure", "vitamin D", "ventricular remodelling", "heart function tests" and "randomized controlled trials". The keywords used in the search were as follows: "cardiac failure", "myocardial failure", "heart decompensation", "left ventricular remodelling", "ventricular remodelling", "ventricular myocardial remodelling", "cholecalciferol", "vitamin D3" and "controlled clinical trials". The time frame for the retrieval was from the establishment of the database to 1 October 2017.

Study selection {#s2b}
---------------

The inclusion criteria were as follows: (1) randomised controlled trials (RCTs) involving the effect of vitamin D on ventricular remodelling in patients with HF with or without blinding methods or allocation concealment methods; (2) parallel or crossover trials; (3) only the data before the washout period were used in a crossover test; (4) available baseline data and changes in the left ventricular end-diastolic dimension (LVEDD) and left ventricular ejection fraction (LVEF); (5) HF defined as New York Heart Association (NYHA) functional class ≥II or LVEF ≤40%; (6) participants of any gender, age or ethnicity; (7) participants without or changing any micronutrient use except for vitamin D and (8) a minimum of 3 months of therapy was necessary for inclusion in the review to ensure that the intervention had sufficient time to produce a better effect. The exclusion criteria were as follows: (1) only the abstract was reported for reference; (2) studies with duplicated data, including the same group of patients or patients for whom there were updated results available; (3) the study had no outcomes of interest; (4) animal studies and reviews; (5) conference documents and (6) non-RCTs, cohort studiers and retrospective studies.

Data extraction and quality assessment {#s2c}
--------------------------------------

Data were independently extracted from each study by two authors (JDZ and JJJ) and entered into a structured spreadsheet followed by a cross-check procedure. Disagreements were resolved by consensus or by a third investigator (PD). The following data were extracted from each trial: the first author's surname, year of publication; demographic and methodological data; total number, mean age, gender distribution and race of enrolled patients; use of or change in drugs for HF; seated LVEDD and LVEF at baseline, when available; number of patients randomly assigned to each intervention; duration of therapy; incidence and type of adverse events; number of dropouts or withdrawals because of adverse events; and change from baseline seated LVEDD and LVEF. Criteria for the RCT risk of bias evaluation listed in the *Cochrane Handbook for Systematic Reviews of Interventions 5.1.0* were adopted, including the following: (1) random sequence generation, (2) allocation concealment, (3) blinding of patients and personnel, (4) blinding of outcome assessment, (5) incomplete outcome data and (6) selective reporting risk. Then, an evaluation system with 'low risk', 'high risk' and 'not clear' was established according to the six criteria described above.[@R23]

Outcomes assessed {#s2d}
-----------------

The primary endpoint was LVEDD, and the secondary endpoints were LVEF and the incidence of adverse reactions.

Data analysis and synthesis {#s2e}
---------------------------

RevMan V.5.3 software was employed for data analysis. Continuous variables are reported as the mean difference (MD) and 95% CI, and the test level was α=0.05. Following clinical heterogeneity analysis of the included studies, statistical heterogeneity was assessed using χ^2^-based Cochran Q statistic and I^2^.[@R24] For the Q statistic, p≥0.1 indicates homogeneity among multiple similar studies, and the fixed-effects model was employed for the meta-analysis, while p\<0.1 indicates statistically significant heterogeneity, and the random-effects model was used for analysis. For the I^2^ statistic, I^2^ \<25% indicates low heterogeneity, while I^2^ \>50% indicates moderate to high heterogeneity.[@R25]

Results {#s3}
=======

Selection and description of studies {#s3a}
------------------------------------

A total of 157 published papers were collected after the initial screening, and eventually, 7 RCTs[@R26] with a total of 465 patients, including 235 cases in the vitamin D group and 230 cases in the control group, were included after reviewing the title, abstract and full text, as well as eliminating duplicate documents, non-RCTs and studies that failed to meet the inclusion criteria. See [figure 1](#F1){ref-type="fig"} for the screening process.

![Flow diagram of study selection.](bmjopen-2017-020545f01){#F1}

In the seven included studies,[@R26] four reported an appropriate randomisation method[@R27]; two adopted allocation concealment[@R29] and six used double-blinding.[@R26] See [figure 2](#F2){ref-type="fig"} for the evaluation of the methodology of the studies.

![Quality assessment.](bmjopen-2017-020545f02){#F2}

Data of the curative effect on the LVEDD were reported in five studies, and the LVEF was reported in all the included studies; two studies mentioned adverse reactions.[@R26] Dropout or withdrawal from the research study was covered in all the included studies. The study characteristics are shown in [table 1](#T1){ref-type="table"}, and the basic information of the included population is shown in [table 2](#T2){ref-type="table"}.

###### 

Study characteristics

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                       Design            Blinding       Vitamin D dose                           Follow-up\   Study population                                               Primary outcome
                                                                                                         duration                                                                    
  ---------------------------- ----------------- -------------- ---------------------------------------- ------------ -------------------------------------------------------------- --------------------------------------------------------------------------------
  Turrini *et al* [@R26]       Prospective RCT   Double-blind   300 000 IU at baseline 50 000 IU/month   6 months     Chronic HF,\                                                   6MWD, echocardiography parameters, hormonal
                                                                                                                      25(OH)D\<20 ng/mL, 60 years＜age                               

  Witte *et al* [@R30]         Prospective RCT   Double-blind   4000 IU/day                              12 months    Chronic HF, NYHA class II--III, LVEF\<45%, 25(OH)D\<20 ng/mL   6MWD, echocardiography parameters

  Qu *et al* [@R31]            Prospective RCT   Single-blind   1000 IU/day                              3 months     NYHA class III--IV                                             Echocardiography parameters,\
                                                                                                                                                                                     BNP, 25(OH)D

  Dalbeni *et al* [@R27]       Prospective RCT   Double-blind   4000 IU/day                              25 weeks     Chronic HF, LVEF\<55%,\                                        Echocardiographic parameters,\
                                                                                                                      NYHA class\>II,\                                               NYHA class,\
                                                                                                                      25(OH)D\<30 ng/mL, Age\>40 years                               NT-proBNP

  Boxer *et al* [@R32]         Prospective RCT   Double-blind   50 000 IU/week                           6 months     Age≥50 years, NYHA class II--IV,\                              Echocardiographic parameters, serum analysis, urine analysis
                                                                                                                      25(OH)D\<37.5 ng/mL                                            

  Shedeed[@R29]                Prospective RCT   Double-blind   1000 IU/day                              12 weeks     Congestive HF, LVEF\<40%,\                                     Echocardiographic parameters
                                                                                                                      LV＞2 SD for age and sex                                       

  Schleithoff *et al* [@R28]   Prospective RCT   Double-blind   2000 IU/day                              9 months     Chronic HF,\                                                   Survival rates, NT-proBNP,\
                                                                                                                      NYHA class II--IV                                              pro-inflammatory and anti-inflammatory cytokines, echocardiographic parameters
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

25(OH)D, 25-hydroxyvitamin D; 6MWD, 6-minute walk distance; HF, heart failure; IU, international units; LV, left ventricular; LVEF, left ventricular ejection fraction; NT, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; RCT, randomised controlled trial.

###### 

Study population characteristics

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                       Intervention        Number (n)   Age (years)   Male (%)     LVEF (%)     NYHA class II (%)   NYHA class III (%)   NYHA class IV (%)   LVEDD (mm)   25(OH)D (ng/mL)   Ischaemic cause (%)   Hypertension\   Diabetes (%)
                                                                                                                                                                                                                          (%)             
  ---------------------------- ------------------- ------------ ------------- ------------ ------------ ------------------- -------------------- ------------------- ------------ ----------------- --------------------- --------------- --------------
  Turrini *et al* [@R26]       Vitamin D           17           77±7          35.3         54.7±13.8    64.7                35.3                 0                   51±1.58      9.4±5.2           41.2                  64.7            35.3

  Placebo                      16                  79±7         43.8          49.2±19.1    68.7         21.3                0                    54±3.48             9.6±7.3      43.7              43.7                  18.7            

  Witte *et al* [@R30]         Vitamin D           80           68.5±12.45    83.8         25.6±10.80   92.5                7.5                  0                   57.6±8.62    38.2±24.81        55.0                  NR              21.3

  Placebo                      83                  69.0±13.78   74.7          26.5±10.62   85.5         14.5                0                    58.0±6.49           36.4±20.24   60.2              NR                    24.1            

  Qu *et al* [@R31]            Vitamin D           22           70±7          59.3         34.9±3.8     NR                  NR                   NR                  NR           NR                NR                    66.7            81.5

  Blank                        17                  69±8         51.8          34.6±3.9     NR           NR                  NR                   NR                  NR           NR                63.0                  85.2            

  Dalbeni *et al* [@R27]       Vitamin D           13           71.2±6.22     84.6         39.08±8.00   58.8\*              50.0†                                    53.9±6.81    16.2±6.59         76.9                  100             NR

  Placebo                      10                  73.4±13.78   60.0          43.6±7.63    41.2\*       50.0†                                    50.6±7.04           16.0±6.15    90                100                   NR              

  Boxer *et al* [@R32]         Vitamin D           19           65.8±10.6     48.4         39.2±13.2    55.0                73.0                 0                   NR           19.1±9.3          25.8                  83.0            51.6

  Placebo                      15                  66.0±10.4    54.5          36.1±14.5    45.0         27.0                0                    NR                  17.8±9.0     30.3              84.8                  42.4            

  Shedeed[@R29]                Vitamin D           42           0.86±1.3      64.29        36.4±2.26    NR                  NR                   NR                  32.81±4.6    13.4±2.21         NR                    NR              NR

  Placebo                      38                  0.93±1.0     57.89         37.2±2.62    NR           NR                  NR                   30.7±5.2            14.0±2.46    NR                NR                    NR              

  Schleithoff *et al* [@R28]   Vitamin D+calcium   42           57±7.41       85.25        32.5±8.67    NR                  NR                   NR                  69.0±8.89    14.4±7.85         47                    38              20

  Placebo+calcium              51                  54±8.89      80.65         33.0±7.56    NR           NR                  NR                   69.0±9.26           15.3±7.48    40                32                    23              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*I and II.

†III and IV.

25(OH)D, 25-hydroxyvitamin D; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; NR, not reported; NYHA, New York Heart Association.

The SD for changes from baseline on the LVEF were reported in four studies.[@R27] According to the *Cochrane Handbook*, the Corr were imputed by averaging the Corr of those four studies, and further imputed the SD for changes from baseline for other studies.[@R26]

The SD for changes from baseline on the LVEDD were reported in three studies.[@R27] According to the *Cochrane Handbook*, the Corr were imputed by averaging the Corr of those three studies, and further imputed the SD for changes from baseline for other studies.[@R26]

Effects of vitamin D on the LVEDD {#s3b}
---------------------------------

Changes in the LVEDD of patients were reported in five studies,[@R26] which showed high levels of heterogeneity among the results of the studies (heterogeneity χ^2^, p=0.07, I^2^=55%), thus supporting analysis using the random-effects model. Compared with the control group, a decrease in the LVEDD was observed in the vitamin D group (MD=−2.31 mm, 95% CI −4.15 to −0.47, p=0.01) ([figure 3](#F3){ref-type="fig"}).

![Forest plot showing the effect of vitamin D on left ventricular end-diastolic dimension.](bmjopen-2017-020545f03){#F3}

Effects of vitamin D on the LVEF {#s3c}
--------------------------------

Changes in the LVEF of patients were reported in all seven studies,[@R26] which showed high levels of heterogeneity among the results of the studies (heterogeneity χ^2^, p\<0.001, I^2^=88%), thus supporting analysis using the random-effects model. Compared with the control group, an increase in the LVEF was observed in the vitamin D group (MD=4.18%, 95% CI 0.36 to 7.99, p=0.03) ([figure 4](#F4){ref-type="fig"}).

![Forest plot showing the effect of vitamin D on left ventricular ejection fraction.](bmjopen-2017-020545f04){#F4}

Subgroup analysis {#s3d}
-----------------

The analysis based on age stratification revealed that compared with the control group both the adults (aged ≥18 years) and non-adults (aged \<18 years) with HF in the vitamin D group showed a decrease in the LVEDD (adults: heterogeneity χ^2^, p=0.65, I^2^=0%；MD=−1.62 mm, 95% CI −2.83 to −0.42, p=0.008; non-adults: MD=−5.51 mm, 95% CI −8.08 to −2.94, p\<0.001) ([figure 5](#F5){ref-type="fig"}). These results, however, need to be interpreted with caution as there was only one study in the subgroup of non-adults.

![Subgroup analysis of effect of vitamin D on left ventricular end-diastolic dimension according to patients' age.](bmjopen-2017-020545f05){#F5}

A subgroup analysis was performed according to the dosage of vitamin D. There was an effect from high-dose vitamin D on the reduction of the LVEDD (heterogeneity χ^2^, p=0.50, I^2^=0%; MD=−1.71 mm, 95% CI −2.95 to −0.46, p=0.007), but this effect was not seen with low-dose vitamin D treatment (heterogeneity χ^2^, p=0.06, I^2^=71%; MD=−3.38 mm, 95% CI −8.23 to 1.48, p=0.17). ([figure 6](#F6){ref-type="fig"}).

![Subgroup analysis of effect of vitamin D on left ventricular end-diastolic dimension (LVEDD) according to dose of vitamin D.](bmjopen-2017-020545f06){#F6}

According to patients with or without reduced ejection fraction, subgroup analyses were performed. Vitamin D supplementation was effective at reducing the LVEDD in patients with reduced ejection fraction (patients with reduced ejection fraction: heterogeneity χ^2^, p=0.07, I^2^=62%；MD=−3.11 mm, 95% CI −5.67 to −0.55, p=0.02; patients without reduced ejection fraction: heterogeneity χ^2^, p=0.76, I^2^=0%；MD=−0.91 mm, 95% CI −2.76 to 0.94, p=0.34) ([figure 7](#F7){ref-type="fig"}). In addition, vitamin D supplementation was effective at increasing the LVEF in patients with reduced ejection fraction (patients with reduced ejection fraction: heterogeneity χ^2^, p=0.02, I^2^=73%; MD=6.21%, 95% CI 2.01 to 10.41, p=0.004; patients without reduced ejection fraction: heterogeneity χ^2^, p=0.002, I^2^=80%; MD=2.74%, 95% CI −1.96 to 7.45, p=0.25) ([figure 8](#F8){ref-type="fig"}).

![Subgroup analysis of effect of vitamin D on left ventricular end-diastolic dimension according to patients with or without reduced ejection fraction.](bmjopen-2017-020545f07){#F7}

![Subgroup analysis of effect of vitamin D on left ventricular ejection fraction according to patients with or without reduced ejection fraction.](bmjopen-2017-020545f08){#F8}

Publication bias {#s3e}
----------------

There was significant asymmetry in the funnel plot for the effect of vitamin D on the LVEDD, which may be due to publication bias and other causes ([figure 9](#F9){ref-type="fig"}). On the other hand, no publication bias was found for the effect of vitamin D on the LVEF ([figure 10](#F10){ref-type="fig"}).

![Funnel plots for the effect of vitamin D on left ventricular end-diastolic dimension.](bmjopen-2017-020545f09){#F9}

![Funnel plots for the effect of vitamin D on left ventricular ejection fraction.](bmjopen-2017-020545f10){#F10}

Adverse event {#s3f}
-------------

Two studies[@R26] reported adverse events. During the follow-up, no significant adverse event was recorded. No data associated with the incidence of adverse events were recorded in the other studies.

Discussion {#s4}
==========

At present, different studies have reported controversial conclusions regarding the influence of vitamin D on ventricular remodelling in patients with HF. The results of this study show that compared with the control group supplementation of vitamin D could reduce the LVEDD (MD=−2.31 mm, 95% CI −4.15 to −0.47, p=0.01) and improve the LVEF (MD=4.18%, 95% CI 0.36 to 7.99, p=0.03) among patients with HF. In addition, a more pronounced effect is achieved using high-dose vitamin D and on patients with a reduced ejection fraction.

Most new treatment methods for chronic HF are expensive and require advanced technologies[@R33]; in addition, most of these treatment methods have not passed strict phase III clinical trials. For patients with HF, vitamin D is not only cheap but also safe, and these patients may obtain more benefits from vitamin D therapy.[@R34] Vitamin D toxicity is based not only on the dosing but also on circulating 25-hydroxyvitamin D (25(OH)D) levels. The Institute of Medicine[@R35] has set the dosage for vitamin D at 4000 IU daily for healthy adults, and the Endocrine Society[@R15] has set a dosage of 10 000 IU daily for patients who are at risk of having circulating 25(OH)D levels\<50 nmol/L. The Institute of Medicine[@R35] considers circulating 25(OH)D levels below 30 nmol/L as deficient, levels between 30 and 49.99 nmol/L as inadequate, levels between 50 and 125 nmol/L as adequate and levels above 125 nmol/L as potentially harmful. In HF, cardiac contraction and diastole are affected due to overload of Ca^2+^ ions in myocardial cells. Lack of vitamin D may intervene with the functions of Ca^2+^ in myocardial cells, thus resulting in cardiomyocyte hypertrophy and intra-organisational inflammatory reaction and fibrosis.[@R36] Low vitamin D levels can activate the renin--angiotensin system,[@R38] give rise to inflammatory reactions[@R39] and result in endothelial dysfunction.[@R40] The effects of vitamin D on the CV system are additionally mediated through elevated parathyroid hormone (PTH) levels, which are associated with the development of left ventricular (LV) hypertrophy.[@R41] Although there is much evidence showing that a lack of vitamin D could result in poor prognosis among patients with HF, different studies have reported controversial conclusions regarding whether supplementation of vitamin D could benefit patients with HF.

In recent years, some relatively small RCTs have studied the influence of vitamin D on patients with HF. In the 2014 World Heart Failure Conference, Louise *et al* [@R42] reported an RCT that performed a 6-month study on 32 patients with HF, and the result showed that supplementation of vitamin D did not improve the LVEF or pro-BNP level. A recent meta-analysis[@R43] also reported that vitamin D supplementation could not improve the LVEF (WMD: 4.11%, 95% CI −0.91 to 9.12, p=0.11) and 6-minute walk distance (6MWD) (WMD: 8.90 m, 95% CI: −48.47 to 66.26, p=0.76) in the treatment of chronic HF. In contrast, this study included three other studies, two of which showed a positive effect from vitamin D supplementation. The present studies have not shown that vitamin D supplementation can improve the 6MWD among patients[@R26]; thus, our meta-analysis did not evaluate this parameter. There are probably many factors that affect exercise tolerance, such as physical condition, obesity, habits and environment, and these confounding factors may obscure the weak force from the remodelled ventricle. However, other studies have drawn opposite conclusions. In 2015, Lowry *et al* [@R46] reported in the European Society of Cardiology a 12-month RCT, and the result showed that for patients with HF supplementation of vitamin D could improve ventricular remodelling (LVEDD −4.46 mm; p=0.047); in addition, the LVEF showed an increasing trend. A non-RCT[@R47] also showed that supplementation of vitamin D could remarkably increase the LVEF value compared with baseline. Elidrissy *et al* [@R48] evaluated 61 cases of children with cardiomyopathy; they concluded, based on the available evidence, that the most likely cause of cardiomyopathy is hypocalcaemia and suggested maternal supplementation of vitamin D during pregnancy and lactation with up to 2000 units of vitamin D and 400 units for their infants for prevention, which was also similar to the results reported by Shedeed.[@R29]

Since there are disputes among different study results, we conducted a meta-analysis of relevant RCT studies to further clarify the influence of vitamin D supplementation on ventricular remodelling in patients with HF. Results of this study show that supplementation of vitamin D inhibits myocardial remodelling and improves cardiac function in patients with HF.

Different studies have different results and conclusions, which may be attributed to the different recommended dosages of vitamin D; since there is no standard recommended dosage of vitamin D at present, there are differences in the recommended dosage of vitamin D in different trials, which may affect the study results. However, there has not been a report related to adverse effects from the dosage of vitamin D. Meanwhile, the study results are related to the selected group; for example, the study results of Schleithoff *et al* [@R28] showed that there were no remarkable changes in the LVEF and LVEDD, and the participants included in this study were predominantly those with NYHA level 3--4 and a high degree of HF, and there was a high rate of lost to follow-up visit (37%).

The data on changes in the LVEDD showed high levels of heterogeneity among studies. Shedeed[@R29] studied the cause of heterogeneity according to subgroup. There was a difference in the metabolism of vitamin D and cardiac recovery capacity between newborns and adults, which might be the cause of heterogeneity.

Although all trials included in this study are RCTs, there are still many limitations in this study (1) because the current studies found that vitamin D has a weak and uncertain effect on ventricular remodelling and cardiac function in patients with HF and cannot improve exercise tolerance or reduce cardiac mortality, additional large-scale clinical studies are needed. Future research needs to focus on whether different vitamin D dosages would be superior; in addition, different selection criteria need to be defined (eg, ejection fraction, vitamin D threshold, PTH threshold, etc) and additional echocardiographic parameters, the 6MWD and cardiovascular mortality need to be evaluated; (2) this study exhibits heterogeneity, and age stratification and whether there is reduced ejection fraction may be sources of clinical heterogeneity according to the subgroup analysis; (3) different recommended dosages of vitamin D are reported in different trials, which may affect study results; therefore, additional trials are required to explore the relationship between vitamin D dosage and effect; (4) the conclusions need to be interpreted with caution as the extent of detected improvement in the remodelling parameters is close to the range of the inter-observer or intra-observer variability of the echocardiographic method itself. The baseline vitamin D level of patients and the follow-up duration may affect the study results, and except for Dalbeni *et al*,[@R27] who have mentioned that no change in therapy was made during follow-up, other studies have not reported adjustments in HF medication. Therefore, whether the weak improvement in the remodelling parameters from vitamin D are attributed to other HF drugs is unclear.

In conclusion, this study shows that supplementation of vitamin D inhibits myocardial remodelling in patients with HF and improves their cardiac function. Vitamin D may be used as adjunctive HF medication for patients with HF with an underlying lack of or insufficiency in vitamin D. This result is encouraging and of great clinical interest but still far from practical implications. The main implication is to encourage further research.
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